The BioCentury Show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.

Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.

The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.

Don't miss this event, every two weeks, now available as a video webcast or audio podcast.

Recent Episodes

Ep. 85 - Stifel’s Opler on Trump 2.0's FDA & the Capital Markets
May 29, 2025 – 32:39
Ep. 84 – Leadership Amid Turmoil: Moonlake CEO Jorge Santos Da Silva
May 20, 2025 – 29:19
Ep. 83 – Europe’s Biotech Moment: Jérôme van Biervliet on Turning Uncertainty into Opportunity
May 1, 2025 – 31:54
Ep. 82 – Act Now or Fall Behind: Michelle Rozo on Biotech’s National Security Stakes
Apr 16, 2025 – 31:01
Ep. 81 - Data-Driven Growth: Immunocore CEO Bahija Jallal on Expanding TCR Therapies
Apr 3, 2025 – 30:52
Ep. 80 - Vertex’s Winning Formula: Altshuler on Choosing the Next Breakthroughs
Mar 20, 2025 – 32:26
Ep. 79 - BNP Paribas’ Moneer on Biotech’s Bull Case: M&A, PE, and Market Recovery
Mar 7, 2025 – 29:33
Ep. 78 - Biotech’s New Normal: SR One’s Simeon George on Adapting to Market Constraints
Feb 20, 2025 – 31:04
Ep. 77 - AI’s Next Leap: Foresite Labs’ Vik Bajaj on Predictive Biology
Feb 6, 2025 – 35:29
Ep. 76 - FDA Inflection Point: Steve Usdin on Biopharma during Trump 2.0
Jan 23, 2025 – 34:01
Ep. 75 - PBMs, IRA, RFK Jr: A Conversation With Rep. Jake Auchincloss
Jan 12, 2025 – 36:04
Ep. 74 - Chris Bardon on Biotech’s Recovery: Valuations, Obesity Drugs, and M&A
Jan 9, 2025 – 34:03
Ep. 73 - Resilience and the CEO’s Paradox: Aoife Brennan on Leading in Biotech
Dec 12, 2024 – 32:12
Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin
Nov 14, 2024 – 35:54
Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments
Oct 31, 2024 – 41:44
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
Oct 17, 2024 – 33:56
Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions
Oct 3, 2024 – 34:36
Ep. 68 - Inside BeiGene: CEO John Oyler on Owning the Drug Development Process
Sep 19, 2024 – 35:08
Ep 67 - AAM's Craig Burton on Opportunities, Challenges of U.S. Biosimilars Market
Sep 5, 2024 – 28:51
Popular Episode - Bob Nelsen on AI, China and the IRA
Aug 22, 2024 – 35:33
Ep. 66 - Jane Grogan on Building Biogen’s Growth Engine
Aug 8, 2024 – 32:23
Ep. 65 - Astellas' Claus Zieler: Global Launches with Local Impact
Jul 25, 2024 – 32:27
Ep. 64 - NPC CEO John O’Brien: Why America Needs an Honest Conversation About Drug Pricing
Jul 11, 2024 – 33:36
Ep. 63 - Day One's Jeremy Bender: Building Pediatric Oncology from the Ground Up
Jun 27, 2024 – 32:27
Ep. 62 - Rick Bright: Navigating the Avian Flu Threat
Jun 13, 2024 – 40:22
Ep. 61 - Vas Narasimhan: How New Data Fit Novartis’ Growth Plan
May 31, 2024 – 32:11
Ep. 60 - JMM John Maraganore: A higher bar for investment is a credit to biotech
May 30, 2024 – 36:00
Ep. 59 - Derek Lowe Unplugged: AI; Biosecure; FDA, Abortion & SCOTUS; and more
May 16, 2024 – 32:09
Ep. 58 - Ysios' Karen Wagner: How Europe's Biotechs Can Rise Above the Noise
May 2, 2024 – 30:54
Ep. 57 - BMS's Robert Plenge: Causal biology is the North Star of R&D
May 2, 2024 – 31:17
Ep. 56 - BIO’s John Crowley on the Biosecure Act
Apr 17, 2024 – 36:55
Ep. 55 - Bruce Booth: Biotech Benefiting from Belt-Tightening
Apr 17, 2024 – 32:10
Ep. 54 - Arthur Caplan: Lessons From a Compassionate Use Firestorm
Apr 17, 2024 – 30:52
Ep. 53 - Bob Nelsen on AI, China and the IRA
Apr 17, 2024 – 35:26
Ep. 52 - Khoo Shih on Scaling Singapore Biotech
Apr 17, 2024 – 31:27